
Advertise on podcast: Beyond Biotech - the podcast from Labiotech
Rating
3.8from
This podcast has
223 episodes
Language
EnglishPublisher
LabiotechExplicit
No
Date created
2022/06/13
Latest episode
2026/11/13
Average duration
36 min.
Release period
8 days
Description
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Unlock Beyond Biotech - the podcast from Labiotech podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from Beyond Biotech - the podcast from Labiotech podcast
Inside Arbor’s CNS pipeline and next-generation gene editing
2026/11/13
Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today.
Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer.
Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies.
01:36 – Meet Devyn Smith
07:48 – Arbor's toolbox approach versus single-editor CRISPR companies
12:16 – What PH1 is and how ABO-101 works
15:19 – Inside the Chiesi partnership for ABO-101
20:14 – Why ALS anchors Arbor's CNS pipeline
26:48 – Arbor's three-year outlook and long-term vision
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
What’s on the horizon for gene editing-based therapies?CRISPR technology’s next wave: Ten companies to watch in 2025 Beyond CRISPR: What CAST could bring to genome editing
How to turn a BIO-Europe meeting into a lasting partnership
2026/11/06
Partnering season is here. As the biopharma community heads to BIO-Europe and the busy end-of-year conference calendar, the question isn’t just who you meet, but how you make those meetings count. In this special episode of Beyond Biotech, we’re talking about the small details that make a big difference at global conferences.
Joining me is Shashi Koduru, Senior Director of Business Development at Vector BioMed. Shashi shares how he plans his on-site schedule, finds the right partners, and makes short meetings productive. We also talk about follow-up, sharing materials after the event, and turning a first conversation into a lasting partnership.
01:15 Meet Shashi Koduru05:13 Vector BioMed’s mission for affordable lentiviral vectors09:36 Cutting through the noise with early conference prep19:04 Making the most of a 30-minute partnering meeting22:46 How a chance BIO encounter became a client25:24 Following up and maintaining momentum after the eventInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Episode 188: How to optimize your biotech company for partnering, licensing, and business successThe ABC of biotech partnershipsNine tips to succeed in pharma-biotech partnerships
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
2026/10/30
Welcome to a special three-part series called 'The Metabolic Moment'.
In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
In part three of our series and ahead of Diabetes Awareness Month, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes, the realities of making gene therapies at scale, and where a potential one-time treatment could fit alongside GLP-1s.
02:21 Meet Ryan Confer and Genprex09:49 What gene therapy can offer patients that GLP-1s cannot12:36 How GPX-002 works and the type 2 diabetes data presented at ASGCT17:22 Working with a CDMO to manufacture an AAV gene therapy at scale20:07 Standing out from GLP-1s and stem cell approaches in diabetes27:59 Diabetes Awareness Month and the prospect of a functional cureInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
The Metabolic Moment: 3 big bets to watch in metabolic diseaseBeyond GLP-1s: is there a new wave of metabolic disease treatments?The future of diabetes treatment: Is a cure possible?
GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
2026/10/23
Welcome to a special three-part series called 'The Metabolic Moment'.
In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants.
02:24 Meet Paul Little05:08 What GLP-1s leave unsolved, from muscle loss to weight rebound10:29 How ATR-258 tunes beta-2 signalling to mimic exercise16:11 Avoiding the cardiovascular side effects of older beta-2 agonists19:03 What the new muscle power and body composition data mean22:03 Phase 2 options, oral advantages and the path to partneringInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
The Metabolic Moment: 3 big bets to watch in metabolic diseaseBeyond Ozempic: the GLP-1 landscape in 2026 What can GLP-1s do beside treat diabetes and obesity?
The next big shake-up in the GLP-1 market? (Part 1 of 3)
2026/10/16
Welcome to a special three-part series called 'The Metabolic Moment'.
In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
In part one of our series, I’m joined by Valeriia Simanovskaia, founder and CEO of BioBrokers, an independent capital markets and strategic advisory firm for life sciences. Trained at Harvard Medical School and based in Paris, Valeriia tracks where the money in biotech is flowing.
02:15 Meet Valeriia and BioBrokers09:07 Discontinuation rates and what they mean for GLP-1 sales12:39 Generic semaglutide arrives in India and Canada16:28 Why oral GLP-1s may become a separate market segment22:15 Amgen’s MariTide and the case for monthly dosing32:00 Why weight maintenance is the next competitive frontierInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
The Metabolic Moment: 3 big bets to watch in metabolic diseaseBeyond Ozempic: the GLP-1 landscape in 2026 Nine biotech companies that could revolutionize obesity treatments
Saudi Arabia's biotech momentum: inside RGMBS 2026
2026/10/09
Saudi Arabia has spent the last four years building one of the most ambitious biotech gatherings in the region: the Riyadh Global Medical Biotechnology Summit. This September, the fourth edition brought together delegations from more than 57 countries and over 200 speakers, closing with more than 40 agreements and initiatives worth over SAR5 billion. From gene editing and genomics to AI-driven drug discovery and biomanufacturing, the Summit is positioning itself as a serious node in the global biotech map — and it's timed deliberately, arriving just weeks before BIO-Europe in Cologne.
To unpack what happened in Riyadh, what it means for Saudi Arabia's biotech ambitions, and how the Summit connects to the conversations happening at BIO-Europe, I'm joined by Abdulaziz Aldayel, a nanomedicine researcher at the King Abdullah International Medical Research Center.
01:20 – Meet Abdulaziz Aldayel07:21 – What RGMBS has set out to achieve since 202111:44 – RGMBS dealmaking jumps to $1.3 billion21:17 – How RGMBS and BIO-Europe complement each other28:14 – What to expect at the next RGMBSThis episode is presented with the support of RGMBS. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Genomes to bioreactors: Saudi Arabia’s gene editing oncology pushSaudi Arabia: is the country set to become a global biotech hub?Saudi Arabia to inject $3B into vaccines and medicines industry
How Flagship's Valo is reshaping AI drug discovery with human data
2026/10/02
AI has been one of the biggest buzzwords in biotech for years now — but for all the technological progress, actual R&D productivity gains have been hard to find, and the cost of developing a new drug keeps climbing. My guest today believes that's because AI alone was never going to be the answer.
Valo, a biotech founded by Flagship Pioneering, is betting on a different approach: combining AI, predictive chemistry, and — crucially — real-world human data from the very start of drug discovery, using access to more than 17 million longitudinal patient records, some spanning 20 years. That approach has already attracted major partners, including a Parkinson's collaboration with EMD Serono worth up to $3 billion and a cardiometabolic disease partnership with Novo.
Joining me to talk about it is Valo's CEO, Brian Alexander — a former practicing radiation oncologist whose years treating patients with aggressive brain tumors helped shape his mission to reimagine how we discover medicines. Brian, welcome to the show.
01:30 — Meet Brian Alexander04:17 — How treating brain tumor patients shaped his mission09:58 — Valo's two-platform approach to drug discovery16:23 — What 20-year patient records reveal about disease22:23 — Why Valo positions itself as pharma's R&D engine32:43 — How this approach could raise clinical success ratesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Episode 198: The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human dataHow human-first datasets are reshaping AI drug discoveryWebinar: How AI has changed drug discovery & development, and what’s coming next
Theialife’s race to bring a childhood myopia treatment to market
2026/09/25
By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision loss later in life. Children face a narrow window in which to intervene, while the eye is still growing, before those structural changes become permanent. Yet despite the scale of the problem, there is still no FDA-approved drug that slows myopia progression in children, a gap underscored just last month when the FDA declined to approve an atropine eye drop for the same use.
My guest today is Thomas Ruggia, President and CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite. Tom joins Theialife after 25 years in ophthalmology leadership, including roles at Johnson & Johnson, Alcon, Novartis, and most recently as CEO of Samsara Vision. We'll talk mechanism, evidence, and the road to Phase 3.
01:49 Meet Thomas Ruggia
06:50 How progressive myopia develops in children and why it's misunderstood
15:55 ND10's mechanism of action
19:51 20 years of Danish compassionate-use data vs. a randomised trial
26:44 Why no FDA-approved pharmacologic therapy exists yet
37:57 Theialife's pipeline beyond myopia
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Innovation in ophthalmology: How biotechs are reshaping the treatment of eye diseasesCan gene therapy treat vision loss?Europe’s Ophthalmology Scene Stays Hot for Biotech Funding
The best biotech conversations you missed this summer
2026/09/18
Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months.
We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of Step Pharma and Gene Mack of Gain Therapeutics, and the unlikely paths that got them there. We'll dig into the science of nonsense mutations with Nerissa Kreher of Alltrna, circular RNA with Lu Gao of Therorna, and a cancer target hiding in human genetics. And we'll close with what these leaders think success actually looks like, years from now.
So sit back, and let's revisit some of our favourite moments from the summer.
02:32 Solving the delivery problem08:39 Founder journeys15:13 Platform science24:41 Business, money, and geopolitics32:28 Looking aheadInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Episode 204: The first PROTAC is here. What comes next in protein degradation?Episode 205: Turning cancer cell dependencies into targeted therapiesEpisode 208: Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson'sEpisode 209: Why Western pharma is sleeping on China's circular RNA revolutionEpisode 211: Beyond biology: Nanobiotix's physics-first approach to cancerEpisode 213: How Evox Therapeutics is targeting CNS diseases with exosomesEpisode 214: Rewriting the rules of genetic medicine with tRNA therapeutics
Rewriting the rules of genetic medicine with tRNA therapeutics
2026/09/11
Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic disease diagnoses, and asks whether a single engineered molecule could address it across many conditions at once.
My guest today is Dr. Nerissa Kreher, Chief Medical Officer of Alltrna. Nerissa brings two decades of rare disease drug development experience, including CMO roles at Entrada Therapeutics, Tiburio Therapeutics, and AVROBIO, to the task of turning that platform thesis into an actual clinical program. We'll talk translation, trial design, and what it takes to bring the first engineered tRNA therapy into the clinic.
02:45 Meet Nerissa Kreher and Alltrna's tRNA platform07:29 Gene-by-gene versus mutation-by-mutation drug development12:08 What nonsense mutations are and why they matter15:55 Phase 1 trial approval in Australia19:49 What basket trials are and FDA receptiveness27:27 Where Alltrna could be in five yearsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Beyond Biotech - Episode 66: treating rare diseases with tRNAWill tRNA therapy be the next big thing in genetic disease treatment?Pharma giants pull back on AAV research: what’s next for the gene therapy space?
How Evox Therapeutics is targeting CNS diseases with exosomes
2026/09/04
Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change. The recent FDA approval of a brain-penetrant enzyme therapy for Hunter syndrome showed that biologics can cross that barrier and work. The next question is whether gene editing can do the same.
My guest today is Dr. Per Lundin, Co-Founder and CEO of Evox Therapeutics, a UK biotech using engineered exosomes to deliver genetic medicines directly into the brain. Evox is now extending that platform from RNA and biologics into gene editing, targeting the genetic drivers of diseases like Huntington's and ALS, where treatment options remain extremely limited. Per also brings a background as a European Patent Attorney and repeat biotech founder. We'll talk delivery, pipeline, and what a commercially scalable genetic medicine for the brain might actually look like.
02:45 Per Lundin's background and Evox's platform09:38 Denali's Hunter syndrome approval and its significance14:58 Targeting MSH3 to treat Huntington's disease20:03 What commercially scalable genetic medicine requires22:13 Evox's dominant IP position in exosome delivery27:34 What success could mean for patients in ten yearsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1BSix exosome therapy companies driving development in the fieldExtracellular vesicles: a growing pipeline still searching for validation
BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech
2026/08/28
Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026.
Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering. For the first time and in response to strong sector demand and growing interest, BIOSPAIN moves to an annual format. Hosted this year in vibrant Bilbao in Spain’s dynamic Basque Country, the event runs from 29 September to 1 October at the Bilbao Exhibition Centre.
In this episode we explore the BIOSPAIN program, the partnering opportunities on offer, the new Talent Day on the final day, and all the practical and logistical details for attendees.
04:02 Why BIOSPAIN is moving to an annual format 05:17 Bilbao and the Basque country09:44 BIOSPAIN 2026: four program tracks13:47 One-on-one partnering 16:10 International participation and a growing Latin American presence 22:27 Talent Day: BIOSPAIN's dedicated biotech job fair 27:48 Ticket options, exhibiting, and sponsorship opportunitiesThis episode is presented with the support of Asebio and BIOSPAIN. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Pharma in Spain: why global investors and innovators are moving inPractical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next stepEpisode 165 - BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year
Beyond biology: Nanobiotix's physics-first approach to cancer
2026/08/21
What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic.
Nanobiotix is a Paris-based biotech pioneering what they call physics-based nanomedicine. Their lead asset is a radioenhancer made of hafnium oxide nanoparticles, designed to be injected directly into a tumor and amplify the destructive power of radiotherapy from within — without increasing damage to surrounding healthy tissue. It is currently in Phase 3 trials in head and neck cancer.
But that's only half the story. The company's Nanoprimer platform is now emerging as a potential new engine for growth — with the promise of making an entirely new class of genetic medicines work better.
02:47 Meet Laurent Lévy06:04 What physics offers that biology cannot 11:12 How JNJ-1900 (NBTXR3) works 15:14 The immune effect 18:16 Pipeline milestones ahead20:56 The Curadigm Nanoprimer platform 25:32 The oversubscribed €85 million raiseInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III ResultsGet to know 15 of the best biotech companies in ParisEight nanotechnology companies to watch out for
How Cancer Research Horizons is building the future of childhood cancer medicines
2026/08/14
Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive. Today's guest is working to change that, and much more besides.
Tony Hickson is Chief Business Officer for Cancer Research Horizons, Cancer Research UK's innovation engine, responsible for turning early-stage science into new treatments, diagnostics, and start-up companies. Tony's career spans big pharma, university tech transfer, and now the translational front line of cancer research, and he's helped build dozens of spinouts along the way. We'll talk about why charity and pharma need each other more than ever, and about C-Further, a bold new push to finally build medicines made for children, not borrowed from adults.
01:25 Meet Tony Hickson05:21 What sets Cancer Research Horizons apart from tech transfer offices12:17 Myrix Bio's exit to Novartis, a standout story15:54 Can patient benefit and commercial success align28:53 Inside C-Further's first two therapeutic programs41:19 How researchers and partners can get involvedInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Episode 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, TurbineCancer Research UK Deploys €700M to Foster Oncology StartupsCancer vaccines: 11 biotechs to keep an eye out for
Why Western pharma is sleeping on China's circular RNA revolution
2026/08/07
RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA.
CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be the most advanced independent circRNA platform in the world — and with barely a single line of English-language press coverage, until now.
My guest today is Dr. Lu Gao, CEO of Therorna Inc., a clinical-stage biotech headquartered in Beijing and Shanghai. The company recently presented three posters at ASGCT in Boston, and their lead program has just entered a first-in-human trial. We're going to talk about the science, the clinical strategy, and why Western pharma hasn't paid enough attention to what's being built in China.
01:33 Meet Lu Gao and Therorna 09:29 How Therorna's approach differs 15:42 How TI-0032 reprograms T cells in the body 21:22 Off-the-shelf and re-dosable: what it means for patients 24:38 Why no Chinese biotech has landed a major in vivo deal 31:27 What a successful US IND clearance would mean Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
The therapeutic potential of circular RNA: Could it soon trump mRNA technology?mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeuticsTherorna funding to accelerate circRNA-based platform
Podcast reviews
Read Beyond Biotech - the podcast from Labiotech podcast reviews
Podcast sponsorship advertising
Start advertising on Beyond Biotech - the podcast from Labiotech relevant audience podcasts
You may also like to advertise on these Podcasts

4.7833521
The Home Service Expert Podcast
Tommy Mello: $200 Million Founder|Forbes, Inc., Entrepreneur Columnist

4.443621369
Something You Should Know
Mike Carruthers | OmniCast Media

4.7906254
Everything is Fine
Jennifer Romolini and Kim France

4.610912581
Serialously with Annie Elise
Annie Elise & Audioboom Studios

4.41171483
The Outlier Health Podcast
Matt Frazier, Matt Tullman, Isabelle Caputo, and Doug Hay

4.616215365
Giggly Squad
Hannah Berner & Paige DeSorbo

4.8219787
Imperfect Action
Steph Taylor

4.727630592
This Past Weekend w/ Theo Von
Theo Von

4.713049379
The Tim Dillon Show
The Tim Dillon Show

4.116091470
The Tucker Carlson Show
Tucker Carlson Network